1.
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Medicine (Baltimore)
; 100(19): e25923, 2021 May 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34106658
RESUMO
ABSTRACT: Blocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.